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doi:10.1016/j.ejvs.2008.01.030Abstract Atherosclerosis is the main contributor to cardiovascular disease and leads to inti-
mal plaque formation, which may progress to plaque rupture with subsequent thromboembolic
events and/or occlusion of the arterial lumen. There is increasing evidence that the develop-
ment or progression of atherosclerosis is associated with advanced glycation endproducts
(AGEs). AGEs are a heterogeneous group of compounds formed by the non-enzymatic reaction
of reducing sugars with proteins, lipids, and nucleic acids. An increased understanding of the
mechanisms of formation and interaction of AGEs has allowed the development of several po-
tential anti-AGE strategies. This review summarizes AGE formation and biochemistry, the
pathogeneic role of AGEs in cardiovascular disease, anti-AGE therapies and clinical relevance
to vascular surgery.
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In 1912, Maillard first reported the non-enzymatic reaction
between reducing sugars and proteins to form proteine
protein cross-links and yellowebrown pigmentation, also
known as advanced glycation endproducts (AGEs). Although
this phenomenon initially was described in food industry,d by Elsevier Ltd. All rights reserved.
Table 2 Abbreviations
AGEs Advanced glycation endproducts
ALEs Advanced lipoxidation endproducts
HbA1c Glycated hemoglobin
RAGE Receptor for AGEs
esRAGE Endogenous secretory RAGE
sRAGE Soluble RAGE
eNOS Endothelial nitric oxide synthase
AFR Autofluorescence reader
IMT Intima-media thickness
MMP Matrix metalloproteinase
126 R. Meerwaldt et al.i.e. the browning that occurs by preparing roasted turkey,
Maillard already hypothesized that this reaction also may
be important in long-term diabetic complications. Over the
last decades, evidence has accumulated that AGEs play an
important role in diabetic complications and in normal
ageing and atherosclerotic degenerative disease.1 With ag-
ing several structural and functional changes occur in the
cardiovascular system and kidneys. These age-related
changes significantly contribute to increased morbidity
and mortality. Although numerous mechanisms are cer-
tainly involved, it has been proposed that these changes
are related partially to increased AGE accumulation.2
This review summarizes AGE formation and biochemis-
try, the pathogeneic role of AGEs in cardiovascular disease
and their potential relevance to vascular surgery.
AGEs: Formation, Tissue Damage, and Clinical
Assessment
The increased accumulation of tissue advanced glycation
end-products (AGEs) is the consequence of a series of
complex and protein reactions. AGE accumulation results
from a combination of hyperglycemia, hyperlipidemia,
oxidative/carbonyl stress and/or decreased renal clearance
of AGE-precursors (Table 1).3,4 The original Maillard hypoth-
esis proposed that chemical modification of proteins by
reducing sugars (glycation of proteins) altered the structure
and function of tissue proteins, precipitating the develop-
ment of diabetic complications.5 Glycation involves the for-
mation of chemically reversible early glycosylation
products with proteins, Schiff bases and Amadori adducts
(e.g. glycated hemoglobin; HbA1c). These early adducts
underwent slow and complex rearrangements to form
advanced glycation end-products (AGEs). The formation of
glycoxidation products depends on oxidizing conditions
and reactive oxygen species.6 Furthermore, Maillard prod-
ucts also are formed via lipid-derived intermediates, result-
ing in advanced lipoxidation products (ALEs)6,7 (all
abbreviations used are summarised in Table 2). Decreased
clearance of serum AGEs may increase tissue AGE accumu-
lation and de novo formation, and absorption of AGEs from
food or smoking may aggravate AGE accumulation.8e11
Assessment of tissue AGE accumulation may serve as
a measure of cumulative metabolic stress and proteinTable 1 Possible sources of the increase in AGE formation
Increased pro-oxidant activity (e.g. age, diabetes,
inflammatory state, bio-incompatibility of dialysis
membrane/solution, infection)
Decreased anti-oxidant activity (e.g. vitamins, selenium,
glutathione system)
Decreased detoxification of AGE precursors
(3-deoxyglucosone reductase)
Less efficient renal excretion of AGE precursors (including
dietary intake)
Hyperglyceamia, insulin resistance
Abnormalities in lipid metabolism (e.g. diminished
clearance, reduced activity lipoprotein lipase)
AGEZ advanced glycation endproducts.damage. Therefore, tissue AGE accumulation may reflect
overall risk instead of single risk factors (e.g. diabetes, or
hyperlipidemia) for developing organ damage.
One major mechanism by which AGEs may contribute to
the development of vascular complications is through
effects on the structure and function of extracellular
matrix components (Fig. 1).12 These AGE-dependent
changes may increase vascular stiffness and permeability
and contribute to extracellular matrix accumulation (Table
3). Decreased degradation of basement membrane compo-
nents and increased binding of plasma proteins may further
enhance accumulation. For instance, AGE modifications ofFigure 1 Extracellular advanced glycation endproducts
(AGEs) may bind several proteins, including lipids and collagen.
The crosslinking of collagen increases vascular stiffness and al-
ters the extracellular matrix. The binding of AGEs to RAGE on
e.g. endothelial cells induces a signaling cascade with nuclear
factor kappa beta (NF-kB) as key signaling factor. NF-kB in-
creases the transcription of different proteins, including endo-
thelin-1, ICAM (intercellular adhesion molecule), VCAM
(vascular cell adhesion molecule), TNF-alpha (tumour necrosis
factor) and interleukines (IL). This cascade aggravates vascular
inflammation and the production of ROS (reactive oxygen spe-
cies). Furthermore, AGEeRAGE interaction induces endothelial
dysfunction by its effect on endothelial nitric oxide (NO) syn-
thase (eNOS). AGEs activate monocytes, causing increased ex-
pression of CD36 receptors leading to increased AGE-lipid (e.g.
AGE-LDL) uptake and foam cell formation.
Table 3 Mechanisms by which AGEs may contribute to
cardiovascular complications
Increased stiffness of connective tissue
Endothelial cells dysfunction: increased permeability,
procoagulant state
Mononuclear cell activation: increase in vascular matrix
Modified LDL: atheroma formation
Quenching NO: endothelial dysfunction, defective artery
relaxation
Reactive oxygen intermediates: increasing oxidative stress
Proinflammatory responses
LDLZ low density lipoproteins, NOZ nitric oxide.
Figure 2 (A) The Autofluorescence Reader illuminates a skin
surface with an excitation light source between 300e420 nm.
Only light from the skin is measured with a spectrometer. (B)
Various fluorescence spectrum results from different subjects:
healthy subject (black line), diabetic patient without cardio-
vascular complications (blue line), diabetic patient with pe-
ripheral artery occlusive disease (green line), hemodialysis
patient with recent myocardial infarction (red line). IZ inten-
sity (a.u.).
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density lipoproteins (LDL), as a consequence of impaired
LDL receptor-mediated clearance, to enhance
inflammation and the development of atherosclerosis.13
Interactions between AGEs and AGE-specific receptors
(RAGE) are a second major mechanism by which AGEs con-
tribute to vascular pathology.14 Although RAGE was first de-
scribed as a receptor for AGEs, an emerging view is that
RAGE is a multiligand receptor of the immunoglobulin
superfamily. By binding to such receptors, AGEs induce or
perpetuate intracellular transduction mechanisms to pro-
duce an array of surface receptors (e.g. endothelial adhe-
sion molecules) and cytokines (e.g. interleukin-1, and
tumour necrosis factor a) (Fig. 1). AGE accumulation also
is directly related to endothelial nitric oxide synthase
(eNOS) production and thereby endothelial dysfunction;15
endothelial RAGE have been proposed as the major key in
such interaction (Table 1).
The characteristic fluorescence spectrum of AGEs at
440 nm, upon excitation at 370 nm, has, been used to de-
termine tissue AGE accumulation, for example in extracts
from homogenates of skin biopsies.16 Biochemical and im-
munochemical assays measure both fluorescent AGEs, like
pentosidine, and non-fluorescent AGEs, such as carboxy-
methyl-lysine.17 HPLC with tandem-mass spectrometry has
evolved as the gold standard for specific AGE assays, but
complexity, cost and lack of reproducibility of this tech-
nique limit its broad use. Moreover, blood and urine sam-
pling of AGE do not necessarily reflect tissue AGE levels.18
Recently, we have developed an instrument, the Auto-
Fluorescence Reader (AFR), designed to non-invasively and
rapidly measure skin auto-fluorescence and therefore AGE
accumulation (Fig. 2). Several studies have shown that skin
auto-fluorescence measured by AFR is strongly related to
AGE accumulation in healthy subjects, diabetic and hemo-
dialysis patients over a broad age range.19,20
AGEs and Atherosclerotic Disease
Carotid stenosis
Carotid intima-media thickness (IMT) is positively associ-
ated with serum concentrations of AGEs.21 Even after cor-
rection for other cardiovascular risk factors, increased
carotid IMT remains correlated with raised AGE levels.
Plasma levels of AGEs in patients on dialysis treatmentare related to carotid IMT and predict further progression
of IMT.22 In an animal study, infusion of AGEs resulted in in-
creased intima thickening of the carotid artery compared
to control animals, independently of the presence of diabe-
tes or hypercholesterolemia.23 RAGE overexpression in pla-
ques from patients undergoing carotid endarterectomy is
associated with plaque inflammation and vulnerability.24
Endogenous secretory receptor for AGEs (esRAGE) binds to
AGEs and is capable of neutralizing AGE action. In type 1 di-
abetic patients, circulating esRAGE is correlated inversely
with carotid IMT.25 Koyama et al. also observed an inverse
relationship between esRAGE and carotid IMT in type 2 dia-
betic patients and non-diabetic subjects.26 Thiazolidine-
diones are a class of drugs currently used clinically for
their insulin-sensitizing activity. These drugs also inhibit
binding of ligands to RAGE. A recent animal study found
that thiazolidinediones inhibit RAGE expression at sites of
carotid injury to inhibit neointima formation.27
Aortic and peripheral artery occlusive disease
AGE accumulation also occurs in atherosclerotic plaques of
the aorta28 and is related to arterial wall stiffness, especially
in hypertensive subjects, independent of age, diabetes or
renal failure.29 In cholesterol-fed animals, AGE deposition
128 R. Meerwaldt et al.in the aortic wall increases with IMT, and treatment with
statins reduced AGE deposition.30
Additionally, AGEs are thought to play a role in features
of peripheral artery occlusive disease (PAD). AGE levels are
higher in type 2 diabetic patients with PAD compared to
those without.31 Furthermore, AGE contents are correlated
inversely to ankle-brachial index, even after correction for
other cardiovascular risk factors. Even in patients without
clinically manifest PAD raised AGE levels are related to ar-
terial wall thickness. For instance, women with a history of
pre-eclampsia appear to have an increased risk for cardio-
vascular disease. We recently showed that in such women
AGE accumulation was related to femoral artery IMT.32
Coronary heart disease
Type 2 diabetic patients with coronary heart disease (CHD)
have higher serum AGEs than patients without CHD. Serum
AGEs correlate with CHD severity.33 AGEs remain associated
with CHD after correction for other cardiovascular risk fac-
tors. Plasma levels of esRAGE are significantly lower in non-
diabetic men with CHD compared to those without.34 The
various AGEs bind RAGE. On the other hand RAGE also binds
non-AGEs (non-advanced glycation endproducts) termed
extracellular newly identified RAGE-binding protein (EN-
RAGE), which may further promote inflammation within
the plaque.35 In coronary lesions from sudden cardiac death
victims, expression of RAGE and EN-RAGE was significantly
greater in diabetic subjects (versus non-diabetics) and
was associated with apoptosis of smooth muscle cells and
macrophages.36
Skin autofluorescence also is increased in (non-diabetic)
persons with stable coronary artery disease and is related
to markers of inflammation.37 Furthermore, skin autofluor-
escence is an independent marker of acute myocardial in-
farction and it predicts major adverse cardiac events
after acute myocardial infarction.37 AGE deposits have
been demonstrated within cardiomyocytes, and serum
levels of AGEs in type 1 diabetic patients are related to iso-
volumetric relaxation time of the left ventricle, a marker of
left ventricular diastolic dysfunction.28,38,39 Also in patients
with end stage renal disease AGE content is related to left
ventricular geometry and with several markers of diastolic
function.39
Prediction of cardiovascular events and mortality
AGEs are not only related to manifestations of cardiovas-
cular disease, they also provide prognostic information.
AGE content predicts adverse cardiac events in patients
after cardiac surgery.40 In patients with heart failure pento-
sidine, one of the most studied AGEs, is a predictor of car-
diac events second only to known risk factors such as left
ventricular mass and B type natriuretic peptide.41
Increased serum levels of AGEs predict total, cardiovas-
cular and coronary mortality in women with type 2 di-
abetes.42 AGE level remained a strong predictor of
survival, even after adjustment for confounding factors, in-
cluding CRP. During long-term follow-up we also observed
that AGEs (skin autofluorescence) were strong predictors
of survival in both diabetic and hemodialysis patients.19,43
In hemodialysis patients, skin autofluorescence is a strongpredictor of cardiovascular mortality, together with history
of CHD, low plasma albumin and high CRP. Multivariate anal-
ysis showed that skin autofluorescence was a stronger pre-
dictor of mortality than traditional risk factors, such as
smoking and lipid profile. Although tissue AGEs are related
to cardiovascular events/mortality, others have suggested
that serum levels of AGEs do not predict future events. How-
ever, serum AGEs may be influenced by dialysis modalities,
absorption from food and smoking.9,10,44 High serum AGEs
might even reflect a better nutritional status, which is asso-
ciated with improved survival.45 Recently, in dialysis
patients we observed that skin autofluorescence, but not
the serum levels of specific AGEs, predicted composite car-
diovascular outcomes (combination of cardiovascular death
and events (unpublished data)). Also others have shown that
tissue fluorescence is a strong predictor of survival in
‘‘healthy’’ subjects.46 Plasma fluorescent products signifi-
cantly and independently predict coronary heart disease in
subjects without history of cardiovascular disease.
Plaque Vulnerability
There is increasing evidence that inflammation plays
a central role in the progression of plaque erosion and
rupture. For instance, plaque macrophages synthesize
matrix metalloproteinases (MMPs), which are capable of
degrading plaque constituents, and thereby are biomarkers
of plaque vulnerability. In humans, RAGE overexpression
has been associated with enhanced inflammatory reactions
at the vulnerable region of the plaque in carotid endarter-
ectomy specimens.24 Plaque studies in-vitro indicated that
AGEs increase MMP levels in a dose-dependent manner. In
an intervention study it has been shown that statin treat-
ment prior to carotid endarterectomy reduces inflamma-
tion, MMPs and RAGE expression.47
Apoptosis is a late hallmark of atherosclerosis associated
with plaque instability and/or rupture.48 Apoptosis might
affect up to 50% of macrophages located in a ruptured pla-
que, a phenomenon which is not seen in a stable athero-
sclerotic plaque. Burke et al. performed a postmortem
analysis of coronary atherosclerotic plaques from patients
with sudden coronary death.36 Expression of RAGE in coro-
nary plaques was associated with apoptotic smooth muscle
cells and macrophages.
The AGEeRAGE axis seems relevant in the progression to
vulnerable plaques. Administration of soluble RAGE (sRAGE)
blocks AGEeRAGE interaction and stabilizes atherosclerotic
lesions and complexity in non-diabetic animals.49 Interven-
tions specifically aimed at AGE-reduction may further help
in understanding the role of AGEseRAGE in the progression
to vulnerable plaques.
AGEs and the Diabetic Foot
In diabetic feet, both macrovascular complications, as
described above, and microvascular complications (neurop-
athy) play important roles. Monnier et al. first described
the relation between AGE accumulation in skin collagen
and the severity of long-term microvascular diabetic com-
plications.16 Sugimoto et al. showed excess deposition of
AGEs in human diabetic peripheral nerves.50 In-vitro AGEs
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tric oxide.51 We have recently shown in diabetic patients
that skin autofluorescence is related to the severity of
both diabetic neuropathy and foot ulceration.52 Although
for this study, the presence of peripheral macrovascular
disease was an exclusion criterion, a complex interrelation-
ship between neuropathy and microvascular disease exists
in diabetic patients. Microvascular disease may worsen ul-
ceration, and endothelial dysfunction has been demon-
strated in relation to both diabetic neuropathy and foot
ulceration.53 AGE accumulation has been reported to
worsen endothelial function and endothelial RAGE has
been proposed as the pivotal molecule. RAGE blockade ac-
celerates wound closure in diabetic mice and suppresses
levels of cytokines such as tumor necrosis factor.54 There-
fore, AGE accumulation may play a role in diabetic foot
ulceration by its effects on neuropathy, on vascular disease
and on delayed wound repair.
AGEs and Graft/Stent Patency
The origin of intimal hyperplasia development is multifac-
torial. AGEs contribute to the formation of neointimal
hyperplasia following acute vessel wall injury.55,56 Two in-
dependent animal studies showed up-regulation of RAGEs
and increased expression of AGEs in the vessel wall after
injury. Blockade of the receptor by sRAGE directly after
injury showed a beneficial effect on the occurrence of neo-
intimal hyperplasia. In-stent re-stenosis of cardiac stents in
(diabetic) patients might be attributed to increased AGEs
and therefore inflammation at the site of the stent. In dia-
betic patients receiving cardiac stents an elevated level of
serum AGEs appeared to be an independent risk factor for
the development of angiographic re-stenosis.57
Cai et al. postulated a relation between graft failure and
increased deposition of AGEs in the vessel wall, located at
the site of intimal hyperplasia in arteriovenous grafts at the
position of the venous anastomoses.58 Serum AGEs are
higher in hemodialysis patients with at least one thrombotic
complication in their history compared to those without.59
Further research is necessary to support positive effects of
anti-AGEs medical treatment in diabetic or hemodialysis
patients receiving vascular interventions.
Anti-AGE Intervention
In diabetes, normalizing high glucose levels may help in
decreasing AGE formation and accumulation.60 The discov-
ery of chemical agents that can inhibit glycation reactions
may have potential therapeutic importance. For instance,
pyridoxamine, has been shown to inhibit AGE formation
and the formation of lipid-derived Maillard products; ad-
vanced lipoxidation endproducts (ALEs).61 Pyridoxamine in-
hibits the development of renal and vascular complications
in obese rats.62 Other less-studied drugs have been shown
to be potent inhibitors of AGE formation. Angiotensin con-
verting enzyme inhibitors, angiotensin II type 1 receptor
blocker, calcium antagonist, statins, all may decrease
AGE formation, probably by reducing oxidative stress.63
A second approach has been focused on the cleavage of
already formed AGEs protein-protein crosslinks. Compoundslike 4,5-dimethyl-3 phenacylthiazolium, also known as ALT-
711, have been tested widely. AGE-breakers have been
shown to break preformed AGE crosslinks, and to improve
arterial compliance in a phase 2 clinical trial in elderly.64
RAGE blockade and restricted dietary intake of AGEs are
new fields of interest in anti-AGE therapies.
Conclusion
AGEs measurements report the cumulative burden of
hyperglycaemia, hyperlipidaemia, oxidative and carbonyl
stress, and renal dysfunction. As a measure of protein
damage AGE may serve as an indicator of over-all risk for
organ damage. Importantly, AGEs are related to the pro-
gression of vascular stenosis and plaque vulnerability. AGEs
predict future cardiovascular morbidity and mortality. Of
great interest is the relationship of AGEs with wound
healing disturbances (e.g. diabetic foot) and its effect on
stent / graft patency. Interventional studies offer the
prospect of reducing AGE accumulation and cardiovascular
risk. Finally, it is important to test whether AGE results
have an effect on final treatment in cardiovascular disease,
such as influencing indications for surgery (plaque vulner-
ability), and increasing operative success (patency). In
conclusion, vascular AGE accumulation has numerous im-
plications for vascular surgery.
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